Fred Jarskog

Dr. Fred Jarskog is a professor of Psychiatry at UNC-Chapel Hill and Research Director of the North Carolina Psychiatric Research Center. He received his medical degree at Wake Forest University School of Medicine and completed his psychiatry residency and fellowship training at UNC-Chapel Hill.  His research is focused on the pathophysiology and treatment of schizophrenia. His work has been funded by the Foundation of Hope, NARSAD, National Institute of Mental Health and in collaboration with industry. Dr. Jarskog has studied novel treatments for cognitive deficits and for treatment-resistant symptoms of schizophrenia. Recently completed and ongoing studies include a histamine 3 antagonist for cognitive deficits, computer-based cognitive remediation for cognitive and functional deficits, and low voltage transcranial stimulation for persistent auditory hallucinations. He continues to study interventions for obesity and associated metabolic problems that commonly occur in people taking antipsychotic medications and he is involved in a multi-site study to test the safety and efficacy of deutetrabenazine for tardive dyskinesia. Dr. Jarskog is also an active clinician, supervising residents in the UNC Schizophrenia Treatment and Evaluation Program (UNC-STEP).He received his medical degree at Wake Forest University School of Medicine and completed his psychiatry residency and fellowship training at UNC-Chapel Hill.  His research is focused on the pathophysiology and treatment of schizophrenia. His work has been funded by the Foundation of Hope, NARSAD, National Institute of Mental Health and in collaboration with industry. Dr. Jarskog has studied novel treatments for cognitive deficits and for treatment-resistant symptoms of schizophrenia. Recently completed and ongoing studies include a histamine 3 antagonist for cognitive deficits, computer-based cognitive remediation for cognitive and functional deficits, and low voltage transcranial stimulation for persistent auditory hallucinations. He continues to study interventions for obesity and associated metabolic problems that commonly occur in people taking antipsychotic medications and he is involved in a multi-site study to test the safety and efficacy of deutetrabenazine for tardive dyskinesia. Dr. Jarskog is also an active clinician, supervising residents in the UNC Schizophrenia Treatment and Evaluation Program (UNC-STEP).